Floatz logo

Venetoclax

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

74 Active assets in the ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
Busulphan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 2/3BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →